Biology Reference
In-Depth Information
218. Resnick KE et al (2009) The detection of differentially expressed microRNAs from the serum
of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol
112(1):55-59
219. Hausler SF et al (2010) Whole blood-derived miRNA profiles as potential new tools for ovar-
ian cancer screening. Br J Cancer 103(5):693-700
220. Li A et al (2010) Pancreatic cancers epigenetically silence SIP1 and hypomethylate and over-
express miR-200a/200b in association with elevated circulating miR-200a and miR-200b
levels. Cancer Res 70(13):5226-5237
221. Wang J et al (2009) MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as
novel blood-based biomarkers of disease. Cancer Prev Res 2(9):807-813
222. Ali S et al (2010) Differentially expressed miRNAs in the plasma may provide a molecular
signature for aggressive pancreatic cancer. Am J Transl Res 3(1):28-47
223. Ho AS et al (2010) Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer.
Transl Oncol 3(2):109-113
224. Zhang C et al (2010) Expression profile of microRNAs in serum: a fingerprint for esophageal
squamous cell carcinoma. Clin Chem 56(12):1871-1879
225. Miyachi M et al (2010) Circulating muscle-specific microRNA, miR-206, as a potential diag-
nostic marker for rhabdomyosarcoma. Biochem Biophys Res Commun 400(1):89-93
226. Yu DC et al (2011) Circulating MicroRNAs: potential biomarkers for cancer. Int J Mol Sci
12(3):2055-2063
227. Gonzales JC et al (2011) Comparison of circulating MicroRNA 141 to circulating tumor
cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response
in patients with metastatic prostate cancer. Clin Genitourin Cancer 9(1):39-45
228. Cheng H et al (2011) Circulating plasma MiR-141 is a novel biomarker for metastatic colon
cancer and predicts poor prognosis. PLoS One 6(3):e17745
229. Nana-Sinkam SP, Croce CM (2011) MicroRNAs as therapeutic targets in cancer. Transl Res
157(4):216-225
230. Markou A, Liang Y, Lianidou E (2011) Review: prognostic, therapeutic and diagnostic poten-
tial of microRNAs in non-small cell lung cancer. Clin Chem Lab Med 49(10):1591-1603
231. Foss KM et al (2011) miR-1254 and miR-574-5p: serum-based microRNA biomarkers for
early-stage non-small cell lung cancer. J Thorac Oncol 6(3):482-488
232. Bianchi F et al (2011) A serum circulating miRNA diagnostic test to identify asymptomatic
high-risk individuals with early stage lung cancer. EMBO Mol Med 3(8):495-503
233. Shen J et al (2011) Diagnosis of lung cancer in individuals with solitary pulmonary nodules
by plasma microRNA biomarkers. BMC Cancer 11(1):374
234. Orom UA, Shiekhattar R (2011) Noncoding RNAs and enhancers: complications of a long-
distance relationship. Trends Genet 27(10):433-439
235. Wapinski O, Chang HY (2011) Long noncoding RNAs and human disease. Trends Cell Biol
21(6):354-361
236. Lee TI et al (2006) Control of developmental regulators by Polycomb in human embryonic
stem cells. Cell 125(2):301-313
237. Boyer LA et al (2006) Polycomb complexes repress developmental regulators in murine
embryonic stem cells. Nature 441(7091):349-353
238. Monteiro J, Fodde R (2010) Cancer stemness and metastasis: therapeutic consequences and
perspectives. Eur J Cancer 46(7):1198-1203
239. Gieni RS, Hendzel MJ (2009) Polycomb group protein gene silencing, non-coding RNA,
stem cells, and cancer. Biochem Cell Biol 87(5):711-746
240. Gupta RA et al (2010) Long non-coding RNA HOTAIR reprograms chromatin state to pro-
mote cancer metastasis. Nature 464(7291):1071-1076
241. Kogo R et al (2011) Long non-coding RNA HOTAIR regulates Polycomb-dependent chro-
matin modification and is associated with poor prognosis in colorectal cancers. Cancer Res
71(20):6320-6326
Search WWH ::
Custom Search